XML 93 R21.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Other Expense (Income) | 3 Months Ended
--- | ---
Mar. 31, 2024
Other Income and Expenses [Abstract] |
Other Expense (Income) | Other Expense (Income) Other expense (income) consists of:
| Three Months Ended March 31, |  |
($ in millions) | 2024 |  | 2023 |  |  |  |
Loss on disposal of plant | $ | — |  |  | $ | 9.4 |  |  |  |  |
Foreign exchange transaction losses | 1.2 |  |  | 0.9 |  |  |  |  |
Contingent consideration | 1.0 |  |  | 0.3 |  |  |  |  |
Asset impairments | 0.6 |  |  | 1.9 |  |  |  |  |
Other items | 0.3 |  |  | 0.4 |  |  |  |  |
Total other expense (income) | $ | 3.1 |  |  | $ | 12.9 |  |  |  |  |
Loss on Disposal of Plant During the three months ended March 31, 2023, the Company recorded expense of $9.4 million within other expense (income), as a result of the sale of one of the Company's manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023. Contingent Consideration Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details. Restructuring and Related Charges In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $22 million to $24 million, with annualized savings in the range of $22 million to $24 million. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:
($ in millions) | Severance and benefits |  |  |  | Other charges |  | Total
Balance, December 31, 2023 | $ | 3.0 |  |  |  |  | $ | — |  |  | $ | 3.0 |
(Credits) charges | — |  |  |  |  | — |  |  | — |
Cash payments | (0.3) |  |  |  |  | — |  |  | (0.3) |
Balance, March 31, 2024 | $ | 2.7 |  |  |  |  | $ | — |  |  | $ | 2.7 |

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 610 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//610/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 720 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//720/tableOfContent + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration